NCT02647359View on ClinicalTrials.gov

Study of Ataluren in Participants With Nonsense Mutation Aniridia

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
Aniridia
Interventions
DRUG

Ataluren

Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.

DRUG

Placebo

Placebo will be administered as per the schedule specified in the respective arm.

Trial Locations (3)

22908

University of Virginia, Charlottesville

97239

Casey Eye Institute, Oregon Health & Science University, Portland

V5Z3N9

University of British Columbia, Vancouver

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY